Literature DB >> 20375900

Management of dyspnea in interstitial lung disease.

Christopher J Ryerson1, Harold R Collard, Steven Z Pantilat.   

Abstract

PURPOSE OF REVIEW: Dyspnea is the most common symptom in interstitial lung disease, yet little is known about its management. This review summarizes the available evidence for the treatment of dyspnea in interstitial lung disease. RECENT
FINDINGS: The management of dyspnea in interstitial lung disease remains a challenge, with few effective therapies. Limited evidence suggests that pulmonary rehabilitation is an effective treatment of dyspnea. In patients with interstitial lung disease, dyspnea severity is associated with measures of ventilatory restriction, gas exchange, functional status, mental health, and some comorbid diseases. Treatment directed toward these modifiable correlates of dyspnea might be effective in dyspnea management; however, the outcome of this strategy has not been adequately studied.
SUMMARY: Studies support pulmonary rehabilitation as an effective treatment for dyspnea in interstitial lung disease and pulmonary rehabilitation should be considered in all dyspneic patients. Several investigational agents have been developed and evaluated for potential use in fibrotic interstitial lung disease; however, these agents have not been shown to improve dyspnea.

Entities:  

Mesh:

Year:  2010        PMID: 20375900     DOI: 10.1097/SPC.0b013e3283392b51

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  6 in total

1.  Respiratory muscles in interstitial lung disease: poorly explored and poorly understood.

Authors:  Bruno Guedes Baldi; João Marcos Salge
Journal:  J Bras Pneumol       Date:  2016-04       Impact factor: 2.624

2.  Does nebulized fentanyl relieve dyspnea during exercise in healthy man?

Authors:  Houssam G Kotrach; Jean Bourbeau; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2015-03-12

3.  Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy.

Authors:  Giacomo Sgalla; Stefania Cerri; Roberto Ferrari; Maria Pia Ricchieri; Stefano Poletti; Margherita Ori; Martina Garuti; Gloria Montanari; Fabrizio Luppi; Kyriakoula Petropulacos; Luca Richeldi
Journal:  BMJ Open Respir Res       Date:  2015-03-10

4.  Psycho-Physiological Associates of Dyspnea in Hospitalized Patients with Interstitial Lung Diseases: A Cross-Sectional Study.

Authors:  Yan Hua Zhou; Yim Wah Mak
Journal:  Int J Environ Res Public Health       Date:  2017-10-24       Impact factor: 3.390

5.  Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15).

Authors:  Yoshinobu Matsuda; Tatsuya Morita; Shunsuke Oyamada; Keisuke Ariyoshi; Takuhiro Yamaguchi; Satoru Iwase
Journal:  BMJ Open       Date:  2021-05-18       Impact factor: 2.692

6.  SINFONIA study protocol: a phase II/III randomised controlled trial examining benefits of guided online group singing in people with chronic obstructive pulmonary disease and interstitial lung disease and their carers.

Authors:  Natasha Smallwood; Amy Pascoe; Sara Vogrin; Jennifer Philip
Journal:  Respir Res       Date:  2022-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.